This trial is active, not recruiting.

Conditions copd, emphysema, chronic bronchitis, smoking
Treatments losartan, placebo
Phase phase 4
Sponsor Johns Hopkins University
Collaborator National Heart, Lung, and Blood Institute (NHLBI)
Start date July 2008
End date August 2013
Trial size 120 participants
Trial identifier NCT00720226, 1 P50 HL084945, 1P50HL084945, NCT00720044


Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage due to smoking. The goal of this study is to determine whether this drug which is also used to treat hypertension can stabilize or improve lung function in people who have from chronic obstructive pulmonary disease (COPD).

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Losartan 100 mg daily
losartan Cozaar
Losartan 100 mg daily
(Placebo Comparator)
Placebo 1 pill daily
placebo "Sugar pill"
Placebo pill daily

Primary Outcomes

Extent of emphysema on CT scan
time frame: Measured at Month 12

Secondary Outcomes

Pulmonary function testing
time frame: Measured at Month 12

Eligibility Criteria

Male or female participants at least 40 years old.

Inclusion Criteria: - Adults with COPD who are either active or former smokers Exclusion Criteria: - Clinical requirement or history of intolerance of angiotensin receptor blockers, serious heart, liver, kidney, neurological disease.

Additional Information

Official title Efficacy of Losartan in Preventing Progression of COPD
Principal investigator Robert A. Wise, MD
Description Participants will be given either losartan in a dose of 50-100 mg per day for a period of one year. During that time, they will have lung function tests, breathing tests, and computed tomograms of the chest. These tests will determine whether there is inflammation in the lung and whether there is progressive involvement of the lung with COPD.
Trial information was received from ClinicalTrials.gov and was last updated in April 2013.
Information provided to ClinicalTrials.gov by Johns Hopkins University.